KVKriti Verma

Kriti Verma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kriti Verma has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Francesca Kinsella

    University Hospital Birmingham NHS Trust, Birmingham, UK

    2 shared publications
  • Jianmin Zuo

    Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK

    2 shared publications
  • Paul Moss

    Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

    2 shared publications
  • Wayne Croft

    Immunology and Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK

    2 shared publications
  • Alexander C. Dowell

    School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UK

    1 shared publication
  • Archana Sharma-Oates

    Affiliations Centre for Computational Biology, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, Institute of Cancer & Genomics, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHD

    by Kriti Verma, Wayne Croft, Sandra Margielewska-Davies, Hayden Pearce, Christine Stephens, Diana Diaconescu, Sarah Bevington, Charles Craddock, Rasoul Amel-Kashipaz, Jianmin Zuo, et al.

    Graft-versus-host disease (GVHD) remains a major challenge after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and further understanding of its immunopathology is crucial for developing new treatments. CD70 interacts with CD27 and is upregulated transiently on T cells after recent T-cell receptor (TCR) engagement. Here, we investigated the functional and clinical significance of CD70 expression on T cells during the early posttransplantation period. CD70 was expressed on a subset of highly activated memory T cells within the first 2 weeks after transplant, which then gradually declined in most patients. CD70+ T cells exhibited an open chromatin landscape and a transcriptional profile indicative of intense Myelocytomatosis oncogene (MYC)-driven glycolysis and proliferation. CD4+ and CD8+CD70+ T-cell numbers increased by ninefold and fourfold, respectively, during acute GVHD (aGVHD) and displayed an oligoclonal TCR repertoire. These cells expressed CCR4 and CCR6 chemokine receptors and were markedly increased in aGVHD tissue samples. Furthermore, CD70+ T cells demonstrated alloreactive specificity in vitro, and proliferative and inflammatory cytokine responses were markedly attenuated by CD70 blockade. These findings identify CD70 as a marker of highly activated alloreactive T cells and reveal the potential therapeutic importance of inhibiting CD27-CD70 costimulation in both the prophylaxis and treatment of aGVHD.


  • Open Access

    PD-1 is imprinted on cytomegalovirus-specific CD4+ T cells and attenuates Th1 cytokine production whilst maintaining cytotoxicity

    by Helen M. Parry, Alexander C. Dowell, Jianmin Zuo, Kriti Verma, Francesca A. M. Kinsella, Jusnara Begum, Wayne Croft, Archana Sharma-Oates, Guy Pratt, Paul Moss

    PD-1 is expressed on exhausted T cells in cancer patients but its physiological role remains uncertain. We determined the phenotype, function and transcriptional correlates of PD-1 expression on cytomegalovirus-specific CD4+ T cells during latent infection. PD-1 expression ranged from 10–85% and remained stable over time within individual donors. This ‘setpoint’ was correlated with viral load at primary infection. PD-1+ CD4+ T cells display strong cytotoxic function but generate low levels of Th1 cytokines which is only partially reversed by PD-1 blockade. TCR clonotypes showed variable sharing between PD-1+ and PD-1- CMV-specific cells indicating that PD-1 status is defined either during T cell priming or subsequent clonal expansion. Physiological PD-1+ CD4+ T cells therefore display a unique ‘high cytotoxicity-low cytokine’ phenotype and may act to suppress viral reactivation whilst minimizing tissue inflammation. Improved understanding of the physiological role of PD-1 will help to delineate the mechanisms, and potential reversal, of PD-1+ CD4+ T cell exhaustion in patients with malignant disease.